Who
Timothy P. Lynch
10% owner
Company insider
Files Form 4 as: 10% owner, AEON Biopharma; Director, Allos Therapeutics; Director, Vaxart; Director, Insite Vision; Director, Bioform Medical; Director, Aradigm.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 1
- Bought
- $485K
- Sold
- $20K
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 10 May 2006
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | AEON AEON BiopharmaBiotechnology | SEC FORM 4 Bought | $243K1,150,000 at $0.2117 | filing |
| 19 Aug 2026filed 21 Aug 2026 | AEON AEON BiopharmaBiotechnology | SEC FORM 4 Bought | $242K1,150,000 at $0.21 | filing |
| 21 Jun 2011filed 23 Jun 2011 | Allos Therapeuticsoption or derivative | SEC FORM 4 Code A | $41K20,000 at $2.06 | filing |
| 25 May 2011filed 27 May 2011 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Dec 2010filed 22 Dec 2010 | Insite Visionoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 22 Jun 2010filed 24 Jun 2010 | Allos Therapeuticsoption or derivative | SEC FORM 4 Code A | $127K20,000 at $6.34 | filing |
| 20 May 2010filed 24 May 2010 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Feb 2010filed 19 Feb 2010 | Bioform Medicaloption or derivative | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 16 Feb 2010filed 19 Feb 2010 | Bioform Medicaloption or derivative | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 16 Feb 2010filed 19 Feb 2010 | Bioform Medicaloption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 16 Feb 2010filed 19 Feb 2010 | Bioform Medicaloption or derivative | SEC FORM 4 Code D | —6,500 at $0.00 | filing |
| 16 Feb 2010filed 19 Feb 2010 | Bioform Medical | SEC FORM 4 Code U | $248K45,454 at $5.45 | filing |
| 16 Dec 2009filed 18 Dec 2009 | Insite Visionoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 10 Dec 2009filed 29 Dec 2009 | Bioform Medicaloption or derivative | SEC FORM 4 Code A | $36K10,000 at $3.61 | filing |
| 17 Nov 2009filed 18 Nov 2009 | VaxartBiotechnology | SEC FORM 4 Sold | $20K3,846 at $5.20 | filing |
| 23 Jun 2009filed 23 Jun 2009 | Allos Therapeuticsoption or derivative | SEC FORM 4 Code A | $147K20,000 at $7.33 | filing |
| 22 May 2009filed 27 May 2009 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Dec 2008filed 16 Dec 2008 | Bioform Medicaloption or derivative | SEC FORM 4 Code A | $11K10,000 at $1.10 | filing |
| 23 Sep 2008filed 25 Sep 2008 | Insite Visionoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jul 2008filed 9 Jul 2008 | Aradigm | SEC FORM 4 Code J | $192K240,000 at $0.80 | filing |
News
No headline names them, or the companies they trade most, lately.